Clinical Progress

An analysis of ADG-126's R&D progress and its clinical results presented at the 2024 ASCO_GI Annual Meeting

18 February 2024
4 min read

On 20 Jan 2024, the latest clinical data of ADG-126 for the treatment of metastatic microsatellite-stable (MSS) colorectal cancer (CRC) were presented in 2024 ASCO_GI. And ADG-126 demonstrated a favorable safety profile and clinical efficacy as monotherapy and in combination with anti-PD-1 therapy.

ADG-126's R&D Progress

ADG-126 is a monoclonal antibody drug developed by Adagene, Inc. It specifically targets CTLA4, a protein involved in regulating the immune system. The drug falls under the therapeutic area of neoplasms, which refers to abnormal growths or tumors. ADG-126 is primarily indicated for the treatment of solid tumors and advanced malignant solid neoplasms. 

According to the Patsnap Synapse, ADG-126 has reached Phase 2 of clinical development globally. And the clinical trial distributions for ADG-126 are primarily in China and Taiwan Provinnce. The key indication is Liver cancer. 

Detailed Clinical Result of ADG-126

This Phase 1b/2, open-label, multicenter dose escalation and expansion study (NCT05405595) was aimed to determine the safety, tolerability and preliminary efficacy of ADG-126 in combo with pembrolizumab (Pembro) in patients (Pts) with metastatic microsatellite-stable (MSS) colorectal cancer (CRC).  

In this study, pts received ADG126 [6 or 10 mg/kg (mpk), Q3W or Q6W, IV] plus Pembro (200 mg, Q3W, IV). Primary endpoints are safety and tolerability. Secondary endpoints are PK, ADA, ORR, DCR, DOR and PFS per RECIST 1.1.

The result showed that as of Aug 29, 2023, a total of 47 Pts have been treated in dose escalation (N=11) and expansion cohorts (N=36). The median age is 60.5 yrs (26-78); 31.9% Pts had at least 3 prior therapies, 12.8% Pts received prior IO therapies. A majority of Pts (74.5%) have what are considered immunologically “cold” tumors. ADG126 was dosed at 6 mpk Q6W (1 Pt) and Q3W (5 Pts), 10 mpk Q6W (17 Pts) and Q3W (24 Pts), and Pembro was dosed at 200 mg Q3W. No DLT or Grade 4/5 TRAE was observed at any dose level. TRAEs more than 10% are pruritis (N=9, 19.1%) and diarrhea (N=5, 10.6%). Grade 3 TRAEs were observed in 5 subjects: 1 G3 diarrhea (6 mpk, 16.7%), 1 G3 adrenal insufficiency (10 mpk Q6W, 5.9%), 1 each G3 pancreatitis, blurred vision and lipase increase (10 mpk Q3W, 12.5%); all TRAEs occurred after repeat dosing. For the MSS CRC expansion cohort, 7 SDs at ADG126 10 mpk Q6W dose level (N=11) were observed, and 2 PRs (including 1 initial PR) and 4 SDs at 10 mpk Q3W (N=13) were observed.

It can be concluded that ADG126/Pembro combination is well-tolerated up to the maximally administered dose of 10 mpk Q3W, with limited G3 TRAEs comparable to Pembro monotherapy. The 10 mpk ADG126 Q3W repeat dosing regimen maintains a favorable safety profile and demonstrates anti-tumor activity. The MSS CRC cohort of 10 mpk ADG126 Q3W surpassed the threshold set for part 1 of the Simon’s 2-stage design, and the second stage of the cohort is now enrolling. In conclusion, ADG126/Pembro has a significantly improved therapeutic index over the same class agents in combination with anti-PD-1 therapy, and encouraging early outcomes in patients of MSS CRC without liver metastasis. 

How to Easily View the Clinical Results Using Synapse Database?

If you want to know the other clinical results of popular conferences, please lick on the “Clinical Results” on the homepage of Patsnap Synapse, which provides multi-dimensional screening and filtering of drugs, indications, targets, companies, result evaluation, release date, popular conferences, etc. to help you quickly locate the data you need. 

Select the clinical meeting you are interested in, such as ESMO. In the results, you can quickly locate the data you want to view by indication, phase and drug name. 

图形用户界面, 文本, 应用程序

描述已自动生成

A single result clearly shows important information such as registration number, phase, indication, Sponsor/Collaborator, biomarker, Trial number, dosing regimen and more. 

图形用户界面, 文本, 应用程序

描述已自动生成

If you would like to view more information about this result, you can go to the result detail page by clicking on the title. 

Above the headings, we provide the original source of the outcome data. The basic information is supplemented with more information beyond the list, such as company, study. design, etc. 

In the important Outcome Measures section, we provide both list and flowchart forms, which are convenient for you to overview the comparison group information and core indicator data. 

Finally, if you need to download these results, you can conveniently check the check boxes on the left side of the list, or directly click the "Export" button to download the data for personalized analysis and file sharing.

Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

MorphoSys to merge with Novartis under a new deal, total purchase price set at €2.7 billion in stock value
Latest Hotspot
3 min read
MorphoSys to merge with Novartis under a new deal, total purchase price set at €2.7 billion in stock value
18 February 2024
MorphoSys AG has officially declared that it has formed a strategic alliance through a Business Merger Contract with Novartis data42 AG and the principal entity, Novartis AG.
Read →
Explore Valacyclovir on Synapse: Tips and Tricks for Better Search Results
Drug Insights
2 min read
Explore Valacyclovir on Synapse: Tips and Tricks for Better Search Results
18 February 2024
Valacyclovir Hydrochloride, sold under the brand name Valtrex, is an antiviral drug that was first approved in the USA in 1995.
Read →
Positive Outcome for Henlius Phase 1 HLX14 Trial Confirmed
Latest Hotspot
3 min read
Positive Outcome for Henlius Phase 1 HLX14 Trial Confirmed
11 February 2024
Henlius Confirms Phase 1 Pharmacokinetic Equivalence Trial of Denosumab HLX14 Achieves Positive Outcome.
Read →
Strategically Search Dicyclomine on Synapse: A How-to Guide
Drug Insights
2 min read
Strategically Search Dicyclomine on Synapse: A How-to Guide
11 February 2024
Dicyclomine Hydrochloride, sold as BENTYL, is an antispasmodic and anticholinergic drug. Introduced in 1950 for Irritable Bowel Syndrome treatment in the US, it has now been removed from the market.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.